Valoctocogene roxaparvovec-rvox

Goal(s):

• Approve valoctocogene roxaparvovec-rvox (ROCTAVIAN) for conditions supported by evidence of benefit.

Length of Authorization:

Once in a lifetime dose.

Requires PA:

Valoctocogene roxaparvovec (billed as pharmacy or provider administered claim)

Covered Alternatives:

- Current PMPDP preferred drug list per OAR 410-121-0030 at www.orpdl.org
- Searchable site for Oregon FFS Drug Class listed at <u>www.orpdl.org/drugs/</u>

Approval Criteria			
1. What diagnosis is being treated?	Record ICD10 code.		
2. Is it the FDA approved indication?	Yes: Go to #3	No: Pass to RPh. Deny; medical appropriateness	
3. Is there documentation that the patient has never received another gene therapy for any diagnosis?	Yes: Go to #4	No: Pass to RPh. Deny; medical appropriateness	
Does the patient have severe Hemophilia A with factor VIII activity of < 1 IU/dL?	Yes: Go to #5	No: Pass to RPh. Deny; medical appropriateness	
5. Is there documentation that the patient does not have factor VIII inhibitors?	Yes: Go to #6 Test date Result	No : Pass to RPh. Deny; medical appropriateness	
6. Is the patient 18 years or older?	Yes : Go to #7	No: Pass to RPh. Deny; medical appropriateness	
7. Has the patient tested negative for adeno- associated virus serotype 5 (AAV5) antibodies as measured by an FDA approved test?	Yes: Go to #8 Test date Result	No: Pass to RPh. Deny; medical appropriateness	

Approval Criteria			
8. Has this patient had a liver health assessment (ALT, AST, bilirubin, alkaline phosphatase, INR, ultrasound or other radiologic assessment) and were all hepatic enzymes and hepatic radiological tests normal? Note: Mild enzyme elevations which are transient and resolved on repeat testing may answer "Yes" to this question.	Yes : Go to # 11	No: Go to #9	
Does the patient have a history of severe liver fibrosis or cirrhosis?	Yes: Pass to RPh. Deny; medical appropriateness	No: Go to #10	
10. Has the patient been evaluated and cleared for gene therapy treatment by a gastroenterologist or hepatologist?	Yes : Go to #11	No: Pass to RPh. Deny; medical appropriateness	
11. Is the patient able and willing to abstain from alcohol for one year following receipt of gene therapy?	Yes : Go to #12	No: Pass to RPh. Deny; medical appropriateness	
12. Is there documentation that the patient does not have any active, acute or chronic infections, including HIV, hepatitis B, or hepatitis C?	Yes : Go to #13	No: Pass to RPh. Deny; medical appropriateness	
13. Is it anticipated that the patient will be able to safely use corticosteroids or other immunosuppressants for at least 8 weeks if needed?	Yes: Approve one lifetime does.	No: Pass to RPh. Deny; medical appropriateness	

P&T/DUR Review: 10/23 (SF) Implementation: 11/1/23